Navigation Links
Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
Date:3/17/2011

South San Francisco, CA, March 18, 2011 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure. This publication reveals, for the first time in a peer reviewed journal, the mechanism of action for omecamtiv mecarbil and the scientific rationale for directly modulating cardiac contractility as an innovative therapeutic strategy for improving cardiac performance in patients with heart failure.

"It is our honor to have Cytokinetics' novel scientific research into direct modulators of the cardiac contractile apparatus published in this prestigious journal," stated Fady I. Malik, MD, FACC, Cytokinetics' Vice President of Biology and Therapeutics and lead author of this report. "This publication summarizes the pioneering work performed by our dedicated research team that has supported the progression of our lead compound, omecamtiv mecarbil, through clinical development and now into Phase IIb clinical trials, which will be conducted by Amgen in collaboration with Cytokinetics."

The publication titled, "Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure," discusses the potential clinical role for therapies that directly activate cardiac myosin in the treatment of systolic heart failure. The authors recognized that decreased cardiac contractility is a central feature of systolic heart failure and that there is a need for more safe and effective treatment options to improve cardiac contractility. Existing drugs that increase cardiac contractility do so indirectly through signaling cascades but their use is limited by their mechanism-related adverse effects. Omecamtiv mecarbil, a small-molecule, direct
'/>"/>

Contact: Christopher Keenan
ckeenan@cytokinetics.com
415-505-2581
Cytokinetics, Inc.
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... ... ... Science and technology continue to improve all aspects of brain tumor care –from ... Chang, MD, director of the Division of Neuro-oncology at UC San Francisco. , Dr. ... development of new treatments and advancing strategies to minimize treatment side effects at the ...
(Date:7/23/2015)... , July 23, 2015 The Hong ... been given the prestigious accolade of "Most Innovative ... its world-class position in fostering innovation and technology ... Asia-Pacific region.  The award ... UK-based innovation and technology magazine and website with ...
(Date:7/23/2015)... ... July 23, 2015 , ... The Pittcon 2016 Program ... S. Mosher Professor of Chemistry and Professor, by courtesy, of Applied Physics at Stanford ... Detection in Solids Led to Super-Resolution Nanoscopy in Cells and Beyond” , Dr. ...
(Date:7/23/2015)... July 23, 2015 Hutchison ... that it has signed a subscription agreement (the ... preference shares held by Mitsui & Co., Ltd. ... Hutchison MediPharma Holdings Limited ("Hutchison MediPharma") (representing 12.24% ... 3,214,404 new ordinary shares in Chi-Med ("Subscription Shares") ...
Breaking Biology Technology:Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3HKSTP Wins Most Innovative Technology Hub at The New Economy Awards 2015 2HKSTP Wins Most Innovative Technology Hub at The New Economy Awards 2015 3The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 2The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 3Mitsui Exchanges its Shares in Hutchison MediPharma for Shares in Chi-Med 2
... , KNOXVILLE, Tenn., Sept. 16 Marking ... colon cancer, EDP Biotech Corporation (EDP), ... today that its ColoMarker(TM) assay achieved 100 percent detection rate ... pre-clinical trials. ColoMarker is the first assay of its kind ...
... SAN DIEGO, Sept. 16 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: ... new class of small molecule compounds based on endogenous adrenal steroid ... Stock Market on September 15, 2009. , , ... Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because its common ...
... Collaboration with Biomodels facilitates development of novel drug product , ... Inc., a biotechnology company developing oral antibodies for disease targets accessible ... a Phase I SBIR grant from the National Institute of Dental ... therapeutic for oral mucositis. , , Avaxia is ...
Cached Biology Technology:New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 2New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 3Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 3Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... personalized medicine for Parkinson,s disease, by investigating signs of ... cells respond to drug treatments. The study was funded ... collected skin cells from patients with genetically inherited forms ... They found that neurons derived from individuals with distinct ...
... is the way to go, if you are a primate ... orangutans, researchers have measured the energy required to navigate a ... up in the trees. Their work was presented at the ... July 2012. The findings help us to understand ...
... Laboratory of Neuro Imaging (LONI) has been responsible for ... generated by the Alzheimer,s Disease Neuroimaging Initiative (ADNI), an ... of Alzheimer,s disease. That stream of ... partners with an ambitious publicprivate effort to dig deeper ...
Cached Biology News:Patient-derived stem cells could improve drug research for Parkinson's 2Patient-derived stem cells could improve drug research for Parkinson's 3Patient-derived stem cells could improve drug research for Parkinson's 4Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 2Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 3
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Biology Products: